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Cavity-Containing Supramolecular Gels as a Crystallization Tool 
for Hydrophobic Pharmaceuticals†  
Lena Kaufmann,
a
 Stuart R. Kennedy,
b
 Christopher D. Jones,
b
 and Jonathan W. Steed
b
*
 
We present two approaches to low-molecular-weight supramolecular gels bearing hydrophobic cavities based on 
calixarene-containing building blocks. Gels are formed by a calixarene based tetrahydrazide gelator or a co-gel of a 
calixarene diammonium salt and a bis-crown ether. The calixarene hydrophobic cavity enables the complexation of 
hydrophobic drug molecules in a generic fashion thus providing an anchor site on the surface of the gel fibre to initiate 
drug crystal nucleation and growth. This technique potentially represents a route to growth of hard-to-nucleate 
polymorphic modifications. The co-gel comprising two components holding together by non-covalent ammonium-crown 
ether interaction can be easily switched back to the sol state by adding competitive binding cations. 
Introduction 
Gels are a class of dynamic soft materials that are becoming 
increasingly important as they might open the way to 
completely new functional systems.
1, 2
  The gel state is defined 
as “a two-component, colloidal dispersion with a continuous 
structure with macroscopic dimensions that is permanent on 
the time scale of the experiment and is solid-like in its 
rheological behaviour”.
3, 4
 Compared with for example 
ceramics, metals or plastic gels are not as long-lasting and 
stable, but instead provide interesting properties, e.g. the 
ability to be switched between gel and sol states by external 
stimuli and free fluid-like diffusion within their structure.
5
 
Traditionally, cross-linked covalent polymers have been used 
as gelators.
6-10
 These polymers are notable for their ability to 
swell up by taking in solvent molecules, in amounts that can 
considerably outweigh their own mass.
11
 In the last two 
decades supramolecular gelation systems based on low-
molecular-weight gelators (LMWGs) have received substantial 
attention owing to their straightforward preparation, 
interesting self-assembly properties and the reversibility of the 
inter-component interactions.
12-20
 In these systems small 
covalent building blocks with a defined chemical structure self-
assemble through non-covalent, weak and reversible 
interactions like hydrogen bonding or π-π-stacking into one-
dimensional fibres. By interconnection of these fibres a self-
supporting three-dimensional network is formed and solvent 
molecules can be trapped within it by surface tension.
13
  
 One emerging potential application of such reversible and 
synthetically versatile gels is in the area of pharmaceutical 
crystallization.
21-25
 Control of polymorphic or solvate form is of 
key industrial importance.
26-29
 Gels based on LMWGs 
represent a highly tuneable medium adaptable to a range of 
solvents including those commonly used in pharmaceutical 
manufacture and they offer the possibility of specific gelator-
solute interactions which may influence the solid form 
outcome and hence make LMWGs a useful part of a 
pharmaceutical solid form screening strategy.
30, 31
 A 
supersaturated mixture of LMWG and solute represents a non-
equilibrium, weakly coupled orthogonal self-assembling 
system in which gel and crystal assembly occurs in a self-
sorting fashion but with the possibility of mutual influence on 
the emergent properties of the whole.
22, 32
 Specifically binding 
of drug molecules to the locally ordered gel fibre surface offers 
a novel heterogeneous nucleation pathway in which the local 
periodicity of the gel may be imparted to the growing crystal 
nucleus, hence potentially subverting the normal polymorphic 
outcome of the crystallization process. In this work we report 
two approaches to the design of broadly applicable gels 
capable of binding, in a generic way, the hydrophobic residues 
of small molecule pharmaceuticals with this application in 
mind. Modern drugs are increasingly hydrophobic.
33
 By 
incorporating a series of hydrophobic cavities into the gel 
fibre
18
 it should be possible to bind an locally ordered layer of 
drug molecules to the gel fibres and, under supersaturation 
conditions, use these sites as the starting point for the 
crystallization of drug solid forms. 
Results and Discussion 
The basic structural element of the target gels incorporates a 
calix[4]arenes whose bowl shaped molecular structure offers a 
hydrophobic cavity suitable for the inclusion of hydrophobic 
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residues of a range of potential solutes.
34-36
 These gelation 
systems should be widely applicable for all kind of drug 
molecules with a residue that can fit into the calixarene cavity. 
Calixarenes can be easily modified at either the upper and/or 
lower rims of the molecular skeleton.
37, 38
 For calixarene 
incorporation into a gel we report two different concepts: 
(1) A one-component approach, in which the calixarene 
monomers are be functionalised with directional hydrogen 
bonding groups to enable them to act as LMWG.  
(2) A two-component approach in which a supramolecular co-
gelator is formed from the non-covalent interaction of two 
components that are non-gelators individually. 
 
A Single Component Gelator 
Compound 1 was designed to produce gel fibres by mutual 
association of the hydrazide groups leaving the calixarene 
cavity exposed on the gel fibre surface. Compound 1 was 
prepared in moderate yield by functionalization of 
calix[4]arene with ethyl bromoacetate
39
 followed by reaction 
with hydrazine hydrate.
40
 The resulting hydrazide was then 
coupled with benzoylhydrazinyl oxobutanoic acid,
41
 leading to 
the desired product 1 with two diformylhydrazine groups (see 
SI for details). The gelation ability of 1 was screened in a wide 
variety of organic solvents but proved to form strong 
reproducible gels only in 1,2-dibromoethane with a critical 
gelation concentration of 1% w/v as evidenced by the vial 
inversion test (Fig. 1b). The resulting gel was analysed by stress 
sweep rheometry (Fig. 2) which revealed a strong gel with a 
plateau G′ value of approximately 10,000 Pa, around an order 
of magnitude higher than G′′ confirming the solid-like nature 
of the material.
42, 43
 SEM images of the dried xerogel (Fig. 1c) 
revealed a fibrous structure typical of self-assembled fibrillar 
networks involving hydrogen bonded chains of gelators.
42
 We 
postulate that gelation occurs by the aggregation mode 
depicted in Fig. 1a. Placing 1 in a concentration of 2 % w/v in a 
non-polar solvent like 1,2-dibromoethane leads to gel 
formation through multiple C=O•••HN hydrogen bonding of 
the diformylhydrazine groups.
19, 44
 
Scheme 1. Structure of gelator 1 and schematic representation 
A Two-Component Co-Gel  
While suitable for proof of principle, compound 1 is not 
particularly versatile in its gelation properties and requires a 
number of steps to prepare. As a result we also investigated 
the preparation of multicomponent co-gels from simpler 
components. A bis(3-aminopropyl) calixarene is readily 
synthesised following the procedure reported by Durmaz
45
 
which yields the tosylate salt 2 (as either the t-butyl form 2a or 
unsubstituted derivative 2b) on protonation with p-
toluenesulfonic acid. Ammonium groups are well known to 
form host-guest complexes with crown ethers
46, 47
 and we 
reasoned that a one dimensional hydrogen bonded polymer 
with potential gelation properties would result from the 
combination of 2 with bis(crown ether) 3.
48
 The proposed 
assembly mode is shown schematically in Fig. 3b. Synthetic 
details are given in the supplementary information. The 
formation of compound 2b was also confirmed by single 
crystal X-ray crystallography as a chloroform solvate. The X-ray 
data is of poor quality and does not permit any quantitative 
description (see SI) but reveals the key gross structural details 
of the cone conformation and 1,3-disubstituted nature of the 
compound with the two ammonium groups situated on the 
(a) (b) 
(c) 
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same side of the calixarene cavity, Fig. 4, supporting the 
assembly mode proposed in Fig 3b. 
  
 
Scheme 2. Structures of gelators 2 and 3 and schematic representations 
Neither 2 nor 3 alone are gelators individually, however, 
after screening 1:1 mixtures of the compounds in a variety of 
solvents we established that a 1:1 mixture of either 2a or 2b 
with 3 in 1,2,4-trichlorobenzene at 6 % w/v results in gel 
formation (Fig. 3a). Gel formation was recognised by a simple 
vial inversion test and confirmed by stress sweep rheology and 
SEM. The solid like nature of the gel was confirmed by the 
much greater plateau value of G′ compared to G′′ (see SI, Fig. 
S1) while the SEM images confirm the fibrillar nature of the 
xerogel. Interestingly the 23 co-gel formed only with tosylate 
counter ions. The analogous hexafluorophosphate or 
trifluoromethanesulfonate salts precipitated instead of 
forming gels in 1,2,4-trichlorobenzene. This anion dependence 
suggests that the gelation properties may be anion controlled 
allowing selective gel turn-off, for example to recover gel 
grown crystals.
21
 In addition, even the tosylate salt of the gel 
can be ‘switched off’ in the presence of potassium ions. An 
aliquot of 10 µl of a saturated solution of KPF6 in acetonitrile 
was carefully layered onto the gel. After 3 hours the whole gel 
collapsed and did not re-form on heating and cooling (Fig. 6). 
The gel was unaffected by acetonitrile alone. This experiment 
suggests that K
+
 can competitively bind with the crown ether 
and break up the hydrogen bonded polymer structure, with 
the strong binding of K
+
 displacing the ammonium ions.
49
 
 
Crystallization experiments 
Preliminary crystallization experiments with model drug 
substances were carried out in order to demonstrate the utility 
of the new calixarene-containing gels in a pharmaceutical 
crystallization context. Compounds tested were paracetamol, 
the NSAID fenbufen (4-(4-biphenyl)-4-oxobutyric acid), the 
depigmentation drug monobenzone (4-(benzyloxy)phenol) and 
the antifungal agent chlorphenesin (3-(p-
chlorophenoxy)propane-1,2-diol). The drug substances were 
dissolved in a hot sol containing either gelator 1 in 1,2-
dibromoethane or mixed gelator 23 in 1,3,5-trichlorobenzene. 
Upon cooling gels formed in a similar way to the gels obtained 
in the absence of the drug solutes. Crystals were recovered 
manually and characterised by X-ray crystallography. The solid 
forms isolated corresponded to the known polymorphs 
obtained via non-gel methods in each case with the exception 
of chlorphenesin, for which the X-ray crystal structure is not 
reported in the CSD and was obtained from a sample produced 
in a gel of 2b3. We were subsequently also able to obtain 
diffraction quality crystals of the same solid form of 
chlorphenesin via solution methods. Interestingly, the 
structure exhibits Z′ = 2 and is based on an extensive network 
of hydrogen bonded rings and chains. It thus fits with Brock’s 
analysis that dialcohol structures should exhibit a tendency 
towards Z′ > 1.
50
 Full structural details are given in the SI. 
These preliminary crystal growth experiments establish the 
feasibility of designing gels with controllable properties 
bearing hydrophobic cavity-containing units and establish 
(a) 
(c) 
(b) 
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proof-of-principle for their application as generally applicable 
pharmaceutical crystallization media for hydrophobic drugs.  
Conclusion  
Two new low-molecular-weight supramolecular gels 
containing hydrophobic cavities have been prepared based on 
either a unimolecular or two-component co-gel system. While 
these first generation LMWG are not particularly versatile 
gelators they establish proof-of-principle that calixarene based 
gelators may be used to crystallise a variety of drug substances 
containing hydrophobic residues. The formation of organic 
crystals within a self-assembled gel medium represents weakly 
coupled orthogonal self-assembly under non-equilibrium 
conditions.
22, 32, 51, 52
 Further work aims to expand the range of 
solvent systems gelled with a view to the discovery of novel 
polymorphic forms and integration of ‘off the shelf’ 
hydrophobic gelators within a polymorph screening method. 
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